Clinical trials: Ophthalmic Solutions
Dry Eye
A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes
The objective of this study was to compare the safety and efficacy of 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- VELOS-2 (NCT03846453)
- Testing
- HL036 Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 637 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Fuchs' Corneal Endothelial Dystrophy (FCED)
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal…
- Trial name
- SPIFD-101 (NCT02653391)
- Testing
- Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Stealth BioTherapeutics Inc.
Dry Eye Disease
A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease
SURF-100 is being studied for the treatment of dry eye disease. SURF-100 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.
- Trial name
- NCT04734197
- Testing
- SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%
- Where
- 40 sites in United States
- Volunteers
- 349 people
- Sponsor
- Surface Ophthalmics, Inc.
Glaucoma
Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma
The primary objective of the study is to assess the safety and tolerability of a 180μg/ml TID dose regimen of recombinant human nerve growth factor (rhNGF) eye drop solution administered over 8 weeks versus a vehicle control in…
- Trial name
- NGF-Glaucoma (NCT02855450)
- Testing
- rhNGF, Vehicle
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Dompé Farmaceutici S.p.A
Post-surgical Ocular Inflammation, Post-surgical Ocular Pain
Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects
SURF-201 is being studied for the treatment of eye inflammation and pain in people who are undergoing cataract surgery. SURF-201 is an investigational drug (which means the study drug is currently being tested) in the form of a…
- Trial name
- NCT04324359
- Testing
- SURF-201
- Where
- 10 sites in United States
- Volunteers
- 91 people
- Sponsor
- Surface Ophthalmics, Inc.
Dry Eye Disease
Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops
The goal of this research is to evaluate and compare the effectiveness of Systane® versus Optive™ on aqueous tear film stability in patients with a diagnosis of Dry Eye Syndrome and to determine the possible application for this…
- Trial name
- NCT00610480
- Testing
- 1st visit Optive, then 2nd visit Systane, 1st visit Systane, then 2nd visit Optive
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Inflammation Eye Pain, Postoperative Cataract
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
- Trial name
- OPTIMIZE-1 (NCT05147233)
- Testing
- OCS-01, Vehicle
- Where
- 25 sites in United States
- Volunteers
- 241 people
- Sponsor
- Oculis
Glaucoma, Primary Open Angle, Ocular Hypertension
Safety and IOP-Lowering Effects of WB007
The study evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This was a 2-part study.
- Trial name
- NCT04149899
- Testing
- WB007 0.05%, WB007 0.15%, WB007 0.4%
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bausch & Lomb Incorporated
Mydriasis
Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation
This study evaluated pupil dilation after administration of fixed combination tropicamide-phenylephrine (TR/PE) vs. phenylephrine (PE) alone and tropicamide (TR) alone. Participants attended 3 visits.
- Trial name
- MIST-1 (NCT03751631)
- Testing
- Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE), Tropicamide 1% ophthalmic solution (TR), Phenylephrine 2.5% ophthalmic solution (PE)
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Eyenovia Inc.
Myopia, Astigmatism
Subjective Comfort With Multipurpose Care Solutions in Soft Contact Lens Wearers
The purpose of this study was to assess the comfort of OPTI-FREE RepleniSH in soft contact lens wearers.
- Conditions
- Myopia, Astigmatism, Refractive Error
- Trial name
- NCT01211535
- Testing
- OPTI-FREE RepleniSH multipurpose solution, ReNu Biotrue multipurpose solution, Silicone hydrogel contact lenses
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Alcon Research
Inflammation, Cataract
Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.
Study to evaluate the safety and tolerability of PRO-155 Ophthalmic Solution 0.09 % in healthy volunteers.
- Trial name
- PRO-155 (NCT01535443)
- Testing
- Bromfenac
- Where
- Mexico
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Allergic Conjunctivitis
Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers
Safety study for bepotastine besilate ophthalmic solution in normal volunteers
- Trial name
- NCT00586625
- Testing
- Bepreve
- Volunteers
- 861 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Ocular Hypertension
Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers
OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteolol and latanoprost in…
- Trial name
- NCT02108288
- Testing
- OPC-1085EL ophthalmic solution, Carteolol long-acting ophthalmic solution, Latanoprost ophthalmic solution
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Conjunctivitis, Allergic
AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal or perennial allergic conjunctivitis.
- Trial name
- NCT02082262
- Testing
- AGN-229666
- Where
- Japan
- Volunteers
- 140 people
- Sponsor
- Allergan
Glaucoma
How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
To determine whether one glaucoma eye drop is less likely to cause changes to the surface of the eye (conjunctiva) than another. The two different prostaglandins are Xalatan and Travatan Z.
- Trial name
- NCT00798694
- Testing
- Xalatan, Travatan Z
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Wills Eye
Primary Open-angle Glaucoma and Ocular Hypertension
Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
This is a randomized, double-masked, parallel-group, multi-center study. Subjects diagnosed with POAG or OHT who meet eligibility criteria at Visit 1 (Screening) will wash out their current topical IOP lowering medication(s), if…
- Trial name
- NCT03858894
- Testing
- DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
- Where
- 13 sites in United States
- Volunteers
- 98 people
- Sponsor
- Santen Inc.
Dry Eye Syndromes
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.
- Trial name
- NCT03162783
- Testing
- ADX-102 Ophthalmic Solution (0.5%), ADX-102 Ophthalmic Solution (0.1%), ADX-102 Ophthalmic Lipid Solution (0.5%)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Diabetic Retinopathy
Nesvategrast (OTT166) in Diabetic Retinopathy (DR)
This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
- Trial name
- NCT05409235
- Testing
- OTT166, Vehicle control
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 225 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Ocular Graft Versus Host Disease
Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)
A Randomized, Double-blinded, Placebo-Controlled Study for the Treatment of Ocular Chronic Graft Verses Host Disease with Processed Amniotic Fluid (pAF) Drops.
- Trial name
- NCT03298815
- Testing
- Amniotic Fluid Eye Drops (AFED), Saline Solution
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Utah
Allergic Conjunctivitis
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen…
- Trial name
- NCT00769886
- Testing
- Ketotifen/naphazoline, Ketotifen, Naphazoline
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Bausch & Lomb Incorporated